| Carcinogen |
0 |
0.8 |
| Pain Management |
0 |
0.35 |
| Fibromyalgia |
0 |
0.32 |
| Anxiety Disorder |
0 |
0.3 |
| Neuropathic Pain |
0 |
0.28 |
| Pain |
0 |
0.27 |
| Acute Pain |
0 |
0.26 |
| Complementary and Alternative Medicine |
0 |
0.26 |
| Skeletal Myoblasts |
0 |
0.25 |
| Cancer Pain |
0 |
0.23 |
| Diabetic Peripheral Neuropathy |
0 |
0.23 |
| Cancer Risk |
0 |
0.19 |
| Diabetic Neuropathy |
0 |
0.19 |
| Generalized Anxiety Disorder |
0 |
0.19 |
| Neuromuscular Blocking Agents |
0 |
0.19 |
| Peripheral Neuropathy |
0 |
0.19 |
| Anticoagulation Therapy |
0 |
0.13 |
| Anxiety |
0 |
0.13 |
| Cancer |
0 |
0.13 |
| Europe |
0 |
0.13 |
| Food and Drug Administration (FDA) |
0 |
0.13 |
| Major Depression |
0 |
0.13 |
| Muscle |
0 |
0.13 |
| Neuropathy |
0 |
0.13 |
| Skeletal |
0 |
0.13 |
| SNRI |
0 |
0.13 |